

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: CARR et al.

Serial No.: To be assigned

Filed: Concurrently herewith

For: CHEMICAL CONSTRUCTS

Commissioner for Patents
Washington, D.C. 20231

H.S.
B/998
9-18-02

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- Copies of the references are enclosed
- Copies of the references were submitted in parent application Serial No. _____ (37 CFR 1.98(d))
- A copy of the International Search Report which issued on International Application No. PCT/GB99/03286 is submitted in herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449. (37 CFR 1.98(d))
- A. The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
- B. The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:
- (1) a final action under § 1.113 or
(2) a notice of allowance under § 1.311,
- whichever occurs first.
- Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$200.00).
- C. The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee.

09/806840

Docket No. PG3565USW

In accordance with the requirements of 37 CFR 1.97(d):

JC08 Rec'd PCT/PTO 05 APR 2001

Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).

The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.


Please charge required fees to Deposit Account No. 07-1392.

A duplicate copy of this paper is attached.

Date:

4/15/2001

Respectfully Submitted,



Frank P. Grassler
Attorney of Record, Reg. No. 31,164

GlaxoSmithKline
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709
Phone: (919) 483-2482
Fax: (919) 483-7988

CERTIFICATE OF EXPRESS MAILING (37 CFR 1.10)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to:
Assistant Commissioner of Patents and Trademarks, Washington, D.C. 20231 on 4/15/01


Marilyn Eldridge